• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA approves first-ever med for Cushing’s syndrome

FDA approves first-ever med for Cushing’s syndrome

February 24, 2012
CenterWatch Staff

The FDA has approved Korlym (mifepristone) 300mg tablets as a once-daily oral medicine to control hyperglycemia secondary to hypercorisolism in adults with endogenous Cushing’s syndrome, according to Corcept Therapeutics.

“We appreciate the FDA’s diligent attention to our NDA and its grant of approval on the PDUFA date,” said Joseph K. Belanoff, M.D., CEO of Corcept. “We plan to make Korlym available to patients by May 1 through a distribution system designed to support both patients and prescribers.”

Korlym 300mg blocks the glucocorticoid receptor type II (GR-II) to which cortisol normally binds. By blocking this receptor, the drug inhibits the effects of excess cortisol in Cushing’s syndrome patients. Korlym 300mg is for patients with diabetes mellitus type 2 or glucose intolerance and have failed surgery or are not candidates for surgery.

“Korlym is a significant advance in the treatment of patients suffering from the debilitating symptoms of Cushing’s syndrome,” said Robert L. Roe, M.D., president of Corcept. “For the first time, these patients have access to an approved therapy when surgery has failed or is not an option.”

The FDA has designated Korlym as an Orphan Drug, a special status designed to encourage the development of medicines for rare diseases and conditions, which will give Corcept marketing exclusivity until February 2019.  Corcept has hired CuraScript SP, a subsidiary of Express Scripts, to dispense the drug.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing